2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

4020 Health-related quality of life in post-transplant patients with newly diagnosed multiple myeloma (NDMM) who received daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in the auriga study

Rebecca Silbermann, MD, Larry D Anderson Jr, MD, PhD2, Laahn Foster, MD3, Alfred Chung, MD4, Chakra P Chaulagain, MD5, Erin M. Pettijohn6, Andrew J. Cowan, MD7, Caitlin Costello, MD8, Sarah M. Larson, MD9, Doug W. Sborov, MD, MS10, Kenneth H. Shain, MD, PhD11, Peter Voorhees, MD12, Mitul Gandhi, MD13, Eva Katz14, Maria Krevvata15, Mai Ngo16, Sharmila Patel, PhD17, Jennifer Phillips18, Vipin Khare, MD19, Thomas S. Lin, MD, PhD20, Ashraf Badros, MD21
1 Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States
2 Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, United States
3 Division of Hematology Oncology, University of Virginia, Charlottesville, Virginia, United States
4 Department of Medicine, University of California San Francisco, San Francisco, California, United States
5 Department of Hematology and Oncology, Myeloma and Amyloidosis Program, Cleveland Clinic Florida, Weston, Florida, United States
6 Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
7 Division of Hematology and Oncology, University of Washington, Seattle, Washington, United States
8 Moores Cancer Center, University of California San Diego, La Jolla, California, United States
9 Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States
10 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
11 Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida, United States
12 Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, North Carolina, United States
13 Virginia Cancer Specialists, Warrenton, Virginia, United States
14 Johnson & Johnson, Raritan, New Jersey, United States
15 Johnson & Johnson, Spring House, Pennsylvania, United States
16 Cytel, Cambridge, Massachusetts, United States
17 Johnson & Johnson, Horsham, Pennsylvania, United States
18 Johnson & Johnson, Horsham, Pennsylvania, United States
19 Johnson & Johnson, Horsham, Pennsylvania, United States
20 Johnson & Johnson, Horsham, Pennsylvania, United States
21 Greenbaum Cancer Center; University of Maryland, Baltimore, Maryland, United States

 Introduction: The phase 3 AURIGA trial (NCT03901963) demonstrated improvements in minimal residual disease (MRD)-negative conversion rates and progression-free survival (PFS) with the addition of subcutaneous daratumumab (DARA SC) to lenalidomide (D-R) maintenance vs R maintenance alone following autologous stem cell transplant (ASCT) in patients (pts) with NDMM. Here we report patient-reported outcomes (PROs), including health-related quality of life (HRQoL), from the final analysis of AURIGA.

Methods: At study entry, eligible pts were aged 18-79 yrs; had NDMM; were in very good partial response or better and MRD positive (10–5 threshold) following ≥4 cycles of anti-CD38–free induction and ASCT; and were enrolled within 6 mos of ASCT. Pts were randomized 1:1 to R maintenance ± DARA SC for 36 (28-day) cycles or until disease progression, unacceptable toxicity, or consent withdrawal. Pts completed 3 PRO assessments: the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item (EORTC QLQ-C30), including the global health status (GHS), physical functioning, pain, and fatigue subscales; the EORTC QLQ Multiple Myeloma Module 20-item (EORTC QLQ-MY20), with the disease symptoms subscale; and the Euro Qol 5-dimensional descriptive system (EQ-5D-5L), including the utility score and visual analog scale (VAS). Questionnaires were completed at baseline (Cycle 1 Day 1); 6, 12, and 24 mos (Cycle 25 Day 1 [C25 D1]) of maintenance; and end of treatment. Results are described through C25 D1. Compliance with PRO assessments was calculated as the number of assessments received divided by the number of assessments expected at each timepoint. Treatment effects within and between groups were assessed by changes from baseline using a mixed-effect model with repeated measures. Time to worsening was evaluated using the Kaplan-Meier method. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated based on a stratified Cox proportional hazards model.

Results: A total of 200 pts were randomized (D-R, n=99; R, n=101). Baseline characteristics were generally well balanced between treatment groups. Compliance rates for PRO assessments were high and comparable between treatment groups at baseline (≥93%), with high rates persisting through C25 D1 (≥78% for all timepoints). At baseline, mean PRO scores were relatively favorable and comparable between treatment groups. Least squares (LS) mean changes from baseline in EORTC QLQ-C30 GHS, physical functioning, pain, and fatigue subscale scores were generally small and similar between treatment groups through C25 D1. Median times to worsening were also comparable between D-R and R for GHS (35.6 vs 35.8 mos), physical functioning (not estimable [NE] in both groups), and fatigue (12.6 vs 13.3 mos). The median time to worsening pain was 24.2 mos in the D-R group vs 35.0 mos in the R group. LS mean changes (95% CI) from baseline in EORTC QLQ-MY20 disease symptom scale scores decreased slightly over time and were similar between D-R and R at C25 D1 (−3.8 [−7.0, −0.5] vs −2.7 [−6.6, 1.2]). No substantial difference was observed between D-R and R for time to worsening of disease symptoms (36.2 vs 51.5 mos; HR 0.93 [95% CI 0.58, 1.50]; P=0.7661). LS mean changes (95% CI) from baseline in the EQ-5D-5L utility score and EQ-5D-5L VAS through C25 D1 were small, and values were generally comparable between D-R and R (at C25 D1: utility score, 0.04 [0, 0.08] vs 0.04 [−0.01, 0.09]; VAS, −0.2 [−3.9, 3.5] vs 2.0 [−2.5, 6.5]). There was no substantial difference in median time to worsening utility score between D-R and R (35.1 mos vs NE; HR 1.24 [95% CI 0.77, 2.00]; P=0.3744), while the median time to worsening VAS was longer for D-R vs R (NE vs 30.0 mos; HR 0.52 [95% CI 0.32, 0.85]; P=0.0074).

Conclusions: In the final analysis of AURIGA, the addition of DARA SC to R maintenance was not associated with meaningful deterioration in HRQoL, symptoms, or functioning vs R alone, as demonstrated by favorable mean PRO scores at baseline that were maintained over the study duration, with no major differences in these scores between treatment groups. Favorable PRO values and responses of VGPR or better at study entry may have limited the ability to detect further improvements in HRQoL, symptoms, or functioning for D-R vs R. Together with improvements in MRD-negative conversion rate and PFS, these data support the use of D-R maintenance following ASCT in pts with NDMM.

Rebecca Silbermann, MD: Sanofi-Aventis - Research Funding; Sanofi-Aventis - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony)